— Know what they know.
Not Investment Advice

NEXI OTC

NexImmune, Inc.
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: -0.0% 1Y: -50.0% 3Y: -100.0% 5Y: -100.0%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Sell · Power 40 · $139 mcap · 1M float · 0.033% daily turnover · Short 75% of daily vol

Balance Sheet Trends

Total Assets
$9M -80.0% ▼
5Y CAGR: -9.5%
Total Liabilities
$5M -52.7% ▼
5Y CAGR: +8.8%
Shareholders Equity
$4M -89.1% ▼
5Y CAGR: -20.1%
Cash & Investments
$5M -86.6% ▼
5Y CAGR: -17.4%
Total Debt
$69K -93.3% ▼
5Y CAGR: -71.3%
Net Debt
-$3M +90.7% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2019FY2020FY2021FY2022FY2023
— Assets —
Cash$9M$5M$30M$35M$3M
Short-Term Investments$1M$1.0B$51M$0$1M
Cash & ST Investments$10M$5M$82M$35M$5M
Net Receivables$6K$0$0$74K$0
Inventory$0$0$0$0$0
Other Current Assets$68K$1M$167K$457K$235K
Total Current Assets$11M$8M$86M$37M$5M
Property, Plant & Equip.$3M$3M$4M$5M$1M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$104K$23K$324K$265K$2M
Total Non-Current Assets$3M$3M$5M$6M$3M
Total Assets$14M$11M$91M$43M$9M
— Liabilities —
Accounts Payable$1M$3M$1M$2M$1M
Short-Term Debt$0$19M$0$0$69K
Deferred Revenue$0$3M$0$0$0
Other Current Liabilities$208K-$30K$0$0-$69K
Total Current Liabilities$3M$27M$7M$10M$5M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$82K$28K$56K$0$0
Total Non-Current Liabilities$82K$28K$56K$426K$0
Total Liabilities$3M$27M$7M$11M$5M
— Equity —
Common Stock$126$126$2K$3K$3K
Retained Earnings-$48M-$78M-$128M-$190M-$223M
Accumulated OCI$506$0$3K$0$0
Total Stockholders Equity$11M-$16M$84M$32M$4M
Total Liabilities & Equity$14M$11M$91M$43M$9M
— Key Metrics —
Total Debt$0$19M$0$1M$69K
Net Debt-$9M$14M-$30M-$34M-$3M
Total Investments$1M$1.0B$51M$0$1M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms